Skip to main content
Division of Gastroenterology & Hepatology Gastroenterology & Hepatology
  1. HOME
  2. Research
  3. Faculty Labs
  4. Schnabl Lab
  5. Publications

Publications

Most significant Research Publications

  1. Iwaisako K, Haimerl M, Paik YH, Taura K, Kodama Y, Sirlin C, Yu E, Yu RT, Downes M, Evans RM, Brenner DA, Schnabl B. Protection from liver fibrosis by a peroxisome proliferator-activated receptor δ agonist. Proc Natl Acad Sci U S A. 2012; 109(21):E1369-76. PMCID: PMC3361396
  2. Wang L, Fouts DE, Stärkel P, Hartmann P, Chen P, Llorente C, DePew J, Moncera K, Ho SB, Brenner DA, Hooper LV, Schnabl B. Intestinal REG3 Lectins Protect Against Alcoholic Steatohepatitis by Reducing Mucosa-associated Microbiota and Preventing Bacterial Translocation. Cell Host Microbe. 2016; 19(2):227–239. PMCID: PMC4786170
  3. Yang A, Inamine T, Hochrath K, Chen P, Wang L, Llorente C, Bluemel S, Hartmann P, Xu J, Koyama Y, Kisseleva T, Torralba MG, Moncera K, Beeri K, Chen CS, Freese K, Hellerbrand C, Lee SM, Hoffman HM, Mehal WZ, Garcia-Tsao G, Mutlu EA, Keshavarzian A, Brown GD, Ho SB, Bataller R, Stärkel P, Fouts DE, Schnabl B. Intestinal fungi contribute to development of alcoholic liver disease. J Clin Invest. 2017; 127(7):2829-2841. PMCID: PMC5490775
  4. Llorente C, Jepsen P, Inamine T, Wang L, Bluemel S, Wang HJ, Loomba R, Bajaj JS, Schubert ML, Sikaroodi M, Gillevet PM, Xu J, Kisseleva T, Ho SB, DePew J, Du X, Sørensen HT, Vilstrup H, Nelson KE, Brenner DA, Fouts DE, Schnabl B. Gastric acid suppression promotes alcoholic liver disease by inducing overgrowth of intestinal Enterococcus. Nat Commun. 2017; 8(1):837. PMCID: PMC5727102
  5. Wang L, Mazagova M, Pan C, Yang S, Brandl K, Liu J, Reilly SM, Wang Y, Miao Z, Loomba R, Lu N, Guo Q, Liu J, Yu RT, Downes M, Evans RM, Brenner DA, Saltiel AR, Beutler B, Schnabl B. YIPF6 Controls Sorting of FGF21 Into COPII Vesicles and Promotes Obesity. Proc Natl Acad Sci U S A. 2019; 116(30):15184-15193. PMCID: PMC6660779
  6. Duan Y, Llorente C, Lang S, Brandl K, Chu H, Jiang L, White RC, Clarke TH, Nguyen K, Torralba M, Shao Y, Liu J, Hernandez-Morales A, Lessor L, Rahman IR, Miyamoto Y, Ly M, Gao B, Sun W, Kiesel R, Hutmacher F, Lee S, Ventura-Cots M, Bosques-Padilla F, Verna EC, Abraldes JG, Brown RS Jr, Vargas V, Altamirano J, Caballería J, Shawcross DL, Ho SB, Louvet A, Lucey MR, Mathurin P, Garcia-Tsao G, Bataller R, Tu XM, Eckmann L, van der Donk WA, Young R, Lawley TD, Stärkel P, Pride D, Fouts DE, Schnabl B. Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease. Nature. 2019, 575(7783):505-511. PMCID: PMC6872939
  7. Duan Y, Chu H, Brandl K, Jiang L, Zeng S, Meshgin N, Papachristoforou E, Argemi J, Mendes BG, Wang Y, Su H, Sun W, Llorente C, Hendrikx T, Liu X, Hosseini M, Kisseleva T, Brenner DA, Bataller R, Ramachandran P, Karin M, Fu W, Schnabl B. CRIg on liver macrophages clears pathobionts and protects against alcoholic liver disease. Nat Commun. 2021; 12(1):7172. PMCID: PMC8660815
  8. Martino C*, Zaramela LS*, Gao B*, Embree M, Tarasova J, Parker SJ, Wang Y, Chu H, Chen P, Lee KC, Galzerani DD, Gengatharan JM, Lekbua A, Neal M, Knight R, Tsukamoto H, Metallo CM, Schnabl B#, Zengler K#. Acetate reprograms gut microbiota during alcohol consumption. Nat Commun. 2022; 13(1):4630. PMCID: PMC9359997
  9. Zeng S, Rosati E, Saggau C, Messner B, Chu H, Duan Y, Hartmann P, Wang Y, Ma S, Huang WJM, Lee J, Lee SM, Carvalho-Gontijo R, Zhang V, Hoffmann JP, Kolls JK, Raz E, Brenner DA, Kisseleva T, LeibundGut-Landmann S, Bacher P, Stärkel P, Schnabl B. Candida albicans-specific Th17 cell-mediated response contributes to alcohol-associated liver disease. Cell Host Microbe. 2023; 31(3):389-404. PMCID: PMC10039706
  10. Yang Y, Duan Y, Lang S, Fondevila MF, Schöler D, Harberts A, Cabré N, Chen S, Shao Y, Vervier K, Miyamoto Y, Zhang X, Chu H, Yang L, Tan C, Eckmann L, Bosques-Padilla F, Verna EC, Abraldes JG, Brown RS Jr, Vargas V, Altamirano J, Caballería J, Shawcross DL, Louvet A, Lucey MR, Mathurin P, Garcia-Tsao G, Bataller R, Stärkel P, Lawley TD, Schnabl B. Targeted inhibition of pathobiont virulence factor mitigates alcohol-associated liver disease. Cell Host Microbe. 2025; 33(6):957-972. PMCID: PMC12162233
  11. Cabré N, Fondevila MF, Wei W, Yamazaki T, Tonetti FR, Eguileor A, Garcia-Carbonell R, Meijnikman AS, Miyamoto Y, Mayo S, Wang Y, Zhang X, Trimbuch T, Lehnardt S, Eckmann L, Fouts DE, Llorente C, Tsukamoto H, Stärkel P, Schnabl B. Activation of intestinal endogenous retroviruses by alcohol exacerbates liver disease. J Clin Invest. 2025; 135(13):e188541 PMCID: PMC12208555

Research Publications

  1. Schwabe RF, Schnabl B, Kweon YO, Brenner DA. CD40 activates NF-kappa B and c-Jun N-terminal kinase and enhances chemokine secretion on activated human hepatic stellate cells. J Immunol. 2001; 166(11):6812-9. PMID: 11359840
  2. Schnabl B, Kweon YO, Frederick JP, Wang XF, Rippe RA, Brenner DA. The role of Smad3 in mediating mouse hepatic stellate cell activation. Hepatology. 2001; 34(1):89-100. PMID: 11431738
  3. Schnabl B, Bradham CA, Bennett BL, Manning AM, Stefanovic B, Brenner DA. TAK1/JNK and p38 have opposite effects on rat hepatic stellate cells. Hepatology. 2001; 34(5):953-63. PMID: 11679966
  4. Schnabl B, Choi YH, Olsen JC, Hagedorn CH, Brenner DA. Immortal activated human hepatic stellate cells generated by ectopic telomerase expression. Lab Invest. 2002; 82(3):323-33. PMID: 11896211
  5. Stefanovic B, Schnabl B, Brenner DA. Inhibition of collagen alpha 1(I) expression by the 5' stem-loop as a molecular decoy. J Biol Chem. 2002; 277(20):18229-37. PMID: 11889120
  6. Schnabl B, Purbeck CA, Choi YH, Hagedorn CH, Brenner D. Replicative senescence of activated human hepatic stellate cells is accompanied by a pronounced inflammatory but less fibrogenic phenotype. Hepatology. 2003; 37(3):653-64. PMID: 12601363
  7. Kweon YO, Paik YH, Schnabl B, Qian T, Lemasters JJ, Brenner DA. Gliotoxin-mediated apoptosis of activated human hepatic stellate cells. J Hepatol. 2003; 39(1):38-46. PMID: 12821042
  8. Stefanovic B, Stefanovic L, Schnabl B, Bataller R, Brenner DA. TRAM2 protein interacts with endoplasmic reticulum Ca2+ pump Serca2b and is necessary for collagen type I synthesis. Mol Cell Biol. 2004; 24(4):1758-68. PMCID: PMC344171
  9. Mühlbauer M, Weiss TS, Thasler WE, Gelbmann CM, Schnabl B, Schölmerich J, Hellerbrand C. LPS-mediated NFkappaB activation varies between activated human hepatic stellate cells from different donors. Biochem Biophys Res Commun. 2004; 325(1):191-7. PMID: 15522218
  10. Schnabl B, Choi YH, Hagedorn CH, Bataller R. DNA microarrays and data mining to study hepatic fibrosis. Methods Mol Med. 2005; 117:359-69. PMID: 16118462
  11. Hu K, Fink M, Froh M, Gäbele E, Hellerbrand C, Mühlbauer M, Wiest R, Schölmerich J, Schnabl B. Characterization of the human zinc finger protein 267 promoter: essential role of nuclear factor Y. Biochim Biophys Acta. 2005; 1729(1):14-23. PMID: 15814297
  12. Schnabl B, Hu K, Mühlbauer M, Hellerbrand C, Stefanovic B, Brenner DA, Schölmerich J. Zinc finger protein 267 is up-regulated during the activation process of human hepatic stellate cells and functions as a negative transcriptional regulator of MMP-10. Biochem Biophys Res Commun. 2005; 335(1):87-96. PMID: 16054593
  13. Meiler C, Muhlbauer M, Johann M, Hartmann A, Schnabl B, Wodarz N, Schmitz G, Scholmerich J, Hellerbrand C. Different effects of a CD14 gene polymorphism on disease outcome in patients with alcoholic liver disease and chronic hepatitis C infection. World J Gastroenterol. 2005; 11(38):6031-7. PMCID: PMC4436730
  14. Wiest R, Jurzik L, Moleda L, Froh M, Schnabl B, von Hörsten S, Schölmerich J, Straub RH. Enhanced Y1-receptor-mediated vasoconstrictive action of neuropeptide Y (NPY) in superior mesenteric arteries in portal hypertension. J Hepatol. 2006; 44(3):512-9. PMID: 16324766
  15. Tacke F, Trautwein C, Yagmur E, Hellerbrand C, Wiest R, Brenner DA, Schnabl B. Up-regulated eotaxin plasma levels in chronic liver disease patients indicate hepatic inflammation, advanced fibrosis and adverse clinical course. J Gastroenterol Hepatol. 2007; 22(8):1256-64. PMID: 17688666
  16. Brandl K, Plitas G, Schnabl B, DeMatteo RP, Pamer EG. MyD88-mediated signals induce the bactericidal lectin RegIII gamma and protect mice against intestinal Listeria monocytogenes infection. J Exp Med. 2007; 204(8):1891-900. PMCID: PMC2118673
  17. Tacke F, Gäbele E, Bataille F, Schwabe RF, Hellerbrand C, Klebl F, Straub RH, Luedde T, Manns MP, Trautwein C, Brenner DA, Schölmerich J, Schnabl B. Bone morphogenetic protein 7 is elevated in patients with chronic liver disease and exerts fibrogenic effects on human hepatic stellate cells. Dig Dis Sci. 2007; 52(12):3404-15. PMID: 17415633
  18. Brandl K, Plitas G, Mihu CN, Ubeda C, Jia T, Fleisher M, Schnabl B, DeMatteo RP, Pamer EG. Vancomycin-resistant enterococci exploit antibiotic-induced innate immune deficits. Nature. 2008; 455(7214):804-7. PMCID: PMC2663337
  19. Schnabl B, Brandl K, Fink M, Gross P, Taura K, Gäbele E, Hellerbrand C, Falk W. A TLR4/MD2 fusion protein inhibits LPS-induced pro-inflammatory signaling in hepatic stellate cells. Biochem Biophys Res Commun. 2008; 375(2):210-4. PMID: 18694726
  20. Miura K, Taura K, Kodama Y, Schnabl B, Brenner DA. Hepatitis C virus-induced oxidative stress suppresses hepcidin expression through increased histone deacetylase activity. Hepatology. 2008; 48(5):1420-9. PMID: 18671304
  21. Gäbele E, Mühlbauer M, Dorn C, Weiss TS, Froh M, Schnabl B, Wiest R, Schölmerich J, Obermeier F, Hellerbrand C. Role of TLR9 in hepatic stellate cells and experimental liver fibrosis. Biochem Biophys Res Commun. 2008; 376(2):271-6. PMID: 18760996
  22. De Minicis S, Seki E, Oesterreicher C, Schnabl B, Schwabe RF, Brenner DA. Reduced nicotinamide adenine dinucleotide phosphate oxidase mediates fibrotic and inflammatory effects of leptin on hepatic stellate cells. Hepatology. 2008; 48(6):2016-26. PMID: 19025999
  23. Brandl K, Rutschmann S, Li X, Du X, Xiao N, Schnabl B, Brenner DA, Beutler B. Enhanced sensitivity to DSS colitis caused by a hypomorphic Mbtps1 mutation disrupting the ATF6-driven unfolded protein response. Proc Natl Acad Sci U S A. 2009; 106(9):3300-5. PMCID: PMC2651297
  24. Kodama Y, Taura K, Miura K, Schnabl B, Osawa Y, Brenner DA. Antiapoptotic Effect of c-Jun N-terminal Kinase-1 through Mcl-1 Stabilization in TNF-induced Hepatocyte Apoptosis. Gastroenterology. 2009; 136(4):1423-34. PMID: 19249395
  25. Kodama Y, Kisseleva T, Iwaisako K, Miura K, Taura K, De Minicis S, Österreicher CH, Schnabl B, Seki E, Brenner DA. C-Jun N-terminal kinase-1 From Hematopoietic Cells Mediates Progression from Hepatic Steatosis to Steatohepatitis and Fibrosis in Mice. Gastroenterology. 2009; 137(4):1467-1477. PMCID: PMC2757473
  26. Miura K, Kodama Y, Inokuchi S, Schnabl B, Aoyama T, Ohnishi H, Olefsky JM, Brenner DA, Seki E. Toll-like receptor 9 promotes steatohepatitis via induction of interleukin-1β in mice. Gastroenterology. 2010; 139(1):323-34. PMCID: PMC4631262
  27. Tacke F, Zimmermann HW, Trautwein C, Schnabl B. CXCL5 plasma levels decrease in patients with chronic liver disease. J Gastroenterol Hepatol. 2011; 26(3):523-9. PMCID: PMC3058722
  28. Yan AW, Fouts DE, Brandl J, Stärkel P, Torralba M, Schott E, Tsukamoto H, Nelson KE, Brenner DA, Schnabl B. Enteric Dysbiosis Associated with a Mouse Model of Alcoholic Liver Disease. Hepatology. 2011; 53(1):96-105. PMCID: PMC3059122
  29. Paik YH, Iwaisako K, Seki E, Inokuchi S, Schnabl B, Osterreicher CH, Kisseleva T, Brenner DA. The nicotinamide adenine dinucleotide phosphate oxidase (NOX) homologues NOX1 and NOX2/gp91(phox) mediate hepatic fibrosis in mice. Hepatology. 2011; 53(5):1730-41. PMCID: PMC3082608
  30. Siggs OM, Schnabl B, Webb B, Beutler B. X-linked cholestasis in mouse due to mutations of the P4-ATPase ATP11C. Proc Natl Acad Sci U S A. 2011; 108(19):7890-5. PMCID: PMC3093471
  31. Schnabl B, Valletta D, Kirovski G, Hellerbrand C. Zinc finger protein 267 is up-regulated in hepatocellular carcinoma and promotes tumor cell proliferation and migration. Exp Mol Pathol. 2011; 91(3):695-701. PMCID: PMC3342774
  32. Schnabl B, Czech B, Valletta D, Weiss TS, Kirovski G, Hellerbrand C. Increased expression of Zinc finger protein 267 in non-alcoholic fatty liver disease. Int J Clin Exp Pathol. 2011; 4(7):661-6. PMCID: PMC3209606
  33. Fouts DE, Torralba M, Nelson KE, Brenner DA, Schnabl B. Bacterial translocation and changes in the intestinal microbiome in mouse models of liver disease. J Hepatol. 2012; 56(6):1283–92. PMCID: PMC3357486
  34. Iwaisako K, Haimerl M, Paik YH, Taura K, Kodama Y, Sirlin C, Yu E, Yu RT, Downes M, Evans RM, Brenner DA, Schnabl B. Protection from liver fibrosis by a peroxisome proliferator-activated receptor δ agonist. Proc Natl Acad Sci U S A. 2012; 109(21):E1369-76. PMCID: PMC3361396
  35. Brandl K, Tomisato W, Li X, Neppl C, Pirie E, Falk W, Xia Y, Moresco EM, Baccala R, Theofilopoulos AN, Schnabl B, Beutler B. Yip1 domain family, member 6 (Yipf6) mutation induces spontaneous intestinal inflammation in mice. Proc Natl Acad Sci U S A. 2012;109(31):12650-5. PMCID: PMC3412000
  36. Hartmann P, Haimerl M, Mazagova M, Brenner DA, Schnabl B. Toll-Like Receptor 2-mediated intestinal injury and enteric Tumor Necrosis Factor Receptor I contribute to liver fibrosis in mice. Gastroenterology. 2012; 143(5):1330-1340. PMCID: PMC3482543
  37. Grivennikov SI, Wang K, Mucida D, Stewart AC, Schnabl B, Jauch D, Taniguchi K, Yu G, Osterreicher CH, Hung KE, Datz C, Feng Y, Fearon ER, Oukka M, Tessarollo L, Coppola V, Yarovinsky F, Cheroutre H, Eckmann L, Trinchieri G, Karin M. Adenoma-linked Barrier Defects and Microbial Products Drive IL-23/IL-17-mediated Tumour Growth. Nature. 2012; 491(7423):254-8. PMCID: PMC3601659
  38. Hartmann P, Chen P, Wang HJ, Wang L, McCole DF, Brandl K, Stärkel P, Belzer C, Hellerbrand C, Tsukamoto H, Ho SB, Schnabl B. Deficiency of intestinal mucin-2 ameliorates experimental alcoholic liver disease in mice. Hepatology. 2013; 58(1):108-19. PMCID: PMC3695050
  39. Patel NS, Peterson MR, Lin GY, Feldstein A, Schnabl B, Bettencourt R, Seki E, Sirlin CB, Loomba R. Insulin resistance increases MRI-estimated pancreatic fat in nonalcoholic fatty liver disease and normal controls. Gastroenterology Research and Practice. 2013; 2013:498296. PMCID: PMC3855930
  40. Wang L, Hartmann P, Haimerl M, Bathena SP, Sjöwall C, Almer S, Alnouti Y, Hofmann AF, and Schnabl B. Nod2 deficiency protects mice from cholestatic liver disease by increasing renal excretion of bile acids. J Hepatol. 2014; 60(6):1259-67. PMCID: PMC4028388
  41. Patel NS, Doycheva I, Peterson MR, Hooker J, Kisselva T, Schnabl B, Seki E, Sirlin CB, Loomba R. Effect of weight loss on magnetic resonance imaging estimation of liver fat and volume in patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2015; 13(3):561-568. PMCID: PMC4333065
  42. Chen P, Stärkel P, Turner JR, Ho SB, Schnabl B. Dysbiosis-induced intestinal inflammation activates tumor necrosis factor receptor I and mediates alcoholic liver disease in mice. Hepatology. 2015; 61(3):883-94. PMCID: PMC4340725
  43. Fang S, Suh JM, Reilly SM, Yu E, Osborn O, Lackey D, Yoshihara E, Perino A, Jacinto S, Lukasheva Y, Atkins AR, Khvat A, Schnabl B, Yu RT, Brenner DA, Coulter S, Liddle C, Schoonjans K, Olefsky JM, Saltiel AR, Downes M, Evans RM. Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance. Nature Medicine. 2015; 21(2):159-165. PMCID: PMC4320010
  44. Mazagova M, Wang L, Anfora AT, Wissmueller M, Lesley SA, Miyamoto Y, Eckmann L, Dhungana S, Pathmasiri W, Sumner S, Westwater C, Brenner DA, Schnabl B. Commensal microbiota is hepatoprotective and prevents liver fibrosis in mice. FASEB J. 2015; 29(3):1043-55. PMCID: PMC4422368
  45. Wang L, Llorente C, Hartmann P, Yang AM, Chen P, Schnabl B. Methods to determine intestinal permeability and bacterial translocation during liver disease. J Immunol Methods. 2015; 421:44-53. PMCID: PMC445127
  46. Chen P, Torralba M, Tan J, Embree M, Zengler K, Stärkel P, van Pijkeren JP, DePew J, Loomba R, Ho SB, Bajaj JS, Mutlu EA, Keshavarzian A, Tsukamoto H, Nelson KE, Fouts DE, Schnabl B. Supplementation of saturated long-chain fatty acids maintains intestinal eubiosis and reduces ethanol-induced liver injury in mice. Gastroenterology. 2015; 148(1):203-214. PMCID: PMC4272436
  47. Arulanandan A, Ang B, Bettencourt R, Hooker J, Behling C, Lin GY, Valasek MA, Ix JH, Schnabl B, Sirlin CB, Loomba R. Association Between Quantity of Liver Fat and Cardiovascular Risk in Patients with Nonalcoholic Fatty Liver Disease Independent of Nonalcoholic Steatohepatitis. Clin Gastroenterol Hepatol. 2015; 13(8):1513-1520. PMID: 25661453
  48. Chen P, Miyamoto Y, Mazagova M, Lee KC, Eckmann L, Schnabl B. Microbiota protects mice against acute alcohol-induced liver injury. Alcohol Clin Exp Res. 2015; 39(12):2313-23. PMCID: PMC4712135
  49. Schnabl B, Farshchi-Heydari S, Loomba R, Mattrey RF, Hoh CK, Sirlin CB, Brenner DA, Behling CA, Vera DR. Staging of Fibrosis in Experimental Non-Alcoholic Steatohepatitis by Quantitative Molecular Imaging in Rat Models. Nuclear Medicine and Biology. 2016; 43(2):179-87. PMID: 26872443
  50. Hartmann P, Seebauer CT, Mazagova M, Horvath A, Wang L, Llorente C, Varki NM, Brandl K, Ho SB, Schnabl B. Deficiency of intestinal mucin-2 protects mice from diet-induced fatty liver disease and obesity. Am J Physiol Gastrointest Liver Physiol. 2016; 310(5):G310-22. PMCID: PMC4773827
  51. Wang L, Fouts DE, Stärkel P, Hartmann P, Chen P, Llorente C, DePew J, Moncera K, Ho SB, Brenner DA, Hooper LV, Schnabl B. Intestinal REG3 Lectins Protect Against Alcoholic Steatohepatitis by Reducing Mucosa-associated Microbiota and Preventing Bacterial Translocation. Cell Host Microbe. 2016; 19(2):227–239. PMCID: PMC4786170
  52. Inamine T, Yang AM, Wang L, Lee KC, Llorente C, Schnabl B. Genetic Loss of Immunoglobulin A Does Not Influence Development of Alcoholic Steatohepatitis in Mice. Alcohol Clin Exp Res. 2016; 40(12):2604-2613. PMCID: PMC5133156
  53. Patel NS, Hooker J, Gonzalez M, Bhatt A, Nguyen P, Ramirez K, Richards L, Rizo E, Hernandez C, Kisseleva T, Schnabl B, Brenner D, Sirlin CB, Loomba R. Weight loss decreases magnetic resonance elastography estimated liver stiffness in nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2017; 15(3):463-464. PMCID: PMC5476292
  54. Eguchi A, Lazaro RG, Wang J, Kim J, Povero D, Willliams B, Ho SB, Stärkel P, Schnabl B, Ohno-Machado L, Tsukamoto H, Feldstein AE. Extracellular vesicles released by hepatocytes from gastric infusion model of alcoholic liver disease contain a MicroRNA barcode that can be detected in blood. Hepatology. 2017; 65(2):475-490. PMCID: PMC5407075
  55. Loomba R, Seguritan V, Li W, Long T, Klitgord N, Bhatt A, Dulai PS, Caussy C, Bettencourt R, Highlander SK, Jones MB, Sirlin CB, Schnabl B, Brinkac L, Schork N, Chen CH, Brenner DA, Biggs W, Yooseph S, Venter JC, Nelson KE.Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease. Cell Metab. 2017; 25(5):1054-1062. PMCID: PMC5502730
  56. Yang A, Inamine T, Hochrath K, Chen P, Wang L, Llorente C, Bluemel S, Hartmann P, Xu J, Koyama Y, Kisseleva T, Torralba MG, Moncera K, Beeri K, Chen CS, Freese K, Hellerbrand C, Lee SM, Hoffman HM, Mehal WZ, Garcia-Tsao G, Mutlu EA, Keshavarzian A, Brown GD, Ho SB, Bataller R, Stärkel P, Fouts DE, Schnabl B. Intestinal fungi contribute to development of alcoholic liver disease. J Clin Invest. 2017; 127(7):2829-2841. PMCID: PMC5490775
  57. Llorente C, Jepsen P, Inamine T, Wang L, Bluemel S, Wang HJ, Loomba R, Bajaj JS, Schubert ML, Sikaroodi M, Gillevet PM, Xu J, Kisseleva T, Ho SB, DePew J, Du X, Sørensen HT, Vilstrup H, Nelson KE, Brenner DA, Fouts DE, Schnabl B. Gastric acid suppression promotes alcoholic liver disease by inducing overgrowth of intestinal Enterococcus. Nat Commun. 2017; 8(1):837. PMCID: PMC5727102
  58. Wang W, Zhao J, Gui W, Sun D, Dai H, Xiao L, Chu H, Du F, Zhu Q, Schnabl B, Huang K, Yang L, Hou X. Tauroursodeoxycholic acid inhibits intestinal inflammation and barrier disruption in mice with non-alcoholic fatty liver disease. Br J Pharmacol. 2018; 175(3):469-484. PMCID: PMC5773980
  59. Ouyang X, Han SN, Zhang JY, Dioletis E, Nemeth BT, Pacher P, Feng D, Bataller R, Cabezas J, Stärkel P, Caballeria J, LePine Pongratz R, Cai SY, Schnabl B, Hoque R, Chen Y, Yang WH, Garcia-Martinez I, Wang FS, Gao B, Torok NJ, Kibbey RG, Mehal WZ. Digoxin Suppresses Pyruvate Kinase M2 Promoted HIF-1a Transactivation in Steatohepatitis. Cell Metab. 2018; 27(2):339-350. PMCID: PMC5806149
  60. Hartmann H, Hochrath K, Horvath A, Chen P, Seebauer CT, Llorente C, Wang L, Alnouti Y, Fouts DE, Stärkel P, Loomba R, Coulter S, Liddle C, Yu RT, Ling L, Rossi SJ, DePaoli AM, Downes M, Evans RM, Brenner DA, Schnabl B. Modulation of the intestinal bile acid/farnesoid X receptor/fibroblast growth factor 15 axis improves alcoholic liver disease in mice. Hepatology. 2018; 67(6):2150-2166. PMCID: PMC5962369
  61. Khanova E, Wang W, Yan R, Chen Y, French SW, Llorente C, Pan SQ, Yang Q, Li Y, Lazaro R, Wu R, Ansong C, Smith RD, Bataller R, Morgan T, Schnabl B, Tsukamoto H. Pyroptosis by Caspase11/4-Gasdermin-D Pathway in Alcoholic Hepatitis in Mice and Patients. Hepatology. 2018; 67(5):1737-1753. PMCID: PMC5906140
  62. Bluemel S, Wang L, Martino C, Lee S, Wang Y, Williams B, Horvath A, Stadlbauer V, Zengler K, Schnabl B. The Role of Intestinal C-type Regenerating Islet Derived-3 Lectins for Non-Alcoholic Steatohepatitis. Hepatology Commun. 2018; 2(4):393-406. PMCID: PMC5880191
  63. Gong S, Lan T, Zeng L, Luo H, Yang X, Li N, Chen X, Liu Z, Li R, Win S, Liu S, Zhou H, Schnabl B, Jiang Y, Kaplowitz N, Chen P. Gut microbiota mediates diurnal variation of acetaminophen induced acute liver injury in mice. J Hepatol. 2018; 69(1):51-59. PMCID: PMC6365016
  64. Caussy C, Hsu C, Lo MT, Liu A, Bettencourt R, Ajmera VH, Bassirian S, Hooker J, Sy E, Richards L, Schork N, Schnabl B, Brenner DA, Sirlin CB, Chen CH, Loomba R for the Genetics of NAFLD in Twins Consortium. Link between gut-microbiome derived metabolite and shared gene-effects with hepatic steatosis and fibrosis in NAFLD. Hepatology. 2018; 68(3):918-932. PMCID: PMC6151296
  65. Brandl K, Hartmann P, Jih LJ, Pizzo DP, Argemi J, Ventura-Cots M, Coulter S, Liddle C, Ling L, Rossi SJ, DePaoli AM, Loomba R, Mehal WZ, Fouts DE, Lucey MR, Bosques-Padilla F, Mathurin P, Louvet A, Garcia-Tsao G, Verna EC, Abraldes JG, Brown RS Jr, Vargas V, Altamirano J, Caballería J, Shawcross D, Stärkel P, Ho SB, Bataller R, Schnabl B. Dysregulation of serum bile acids and FGF19 in alcoholic hepatitis. J Hepatol. 2018; 69(2):396-405. PMCID: PMC6054564
  66. Chen Y, Ouyang X, Hoque R, Garcia-Martinez I, Yousaf MN, Tonack S, Offermanns S, Dubuquoy L, Louvet A, Mathurin P, Massey V, Schnabl B, Bataller R, Mehal WZ. B-hydroxybutyrate protects from alcoholic hepatitis via a Hcar2-cAMP dependent pathway. J Hepatol. 2018; 69(3):687-696. PMCID: PMC6098974
  67. Zhong Z, Liang S, Sanchez-Lopez E, He F, Shalapour S, Lin XJ, Wong J, Ding S, Seki E, Schnabl B, Hevener AL, Greenberg HB, Kisseleva T, Karin M. New mitochondrial DNA synthesis enables NLRP3 inflammasome activation. Nature. 2018; 560(7717):198-203. PMCID: PMC6329306
  68. Caussy C, Hsu C, Singh S, Bassirian S, Kolar J, Faulkner C, Sinha N, Bettencourt R, Gara N, Valasek MA, Schnabl B, Richards L, Brenner DA, Hofmann AF, Loomba R. Serum bile acid patterns are associated with the presence of NAFLD in twins, and dose-dependent changes with increase in fibrosis stage in patients with biopsy-proven NAFLD. Aliment Pharmacol Ther. 2019; 49(2):183-193. PMCID: PMC6319963
  69. Hendrikx T, Duan Y, Wang Y, Oh JH, Alexander LM, Huang W, Stärkel P, Ho SB, Gao B, Fiehn O, Emond P, Sokol H, van Pijkeren JP, Schnabl B. Bacteria Engineered to Produce IL22 in Intestine Induce Expression of REG3G to Reduce Ethanol-induced Liver Disease in Mice. Gut. 2019; 68(8):1504-1515. PMCID: PMC6387784
  70. Gong S, Yan Z, Liu Z, Niu M, Fang H, Li N, Huang C, Li L, Chen G, Luo H, Chen X, Zhou H, Hu J, Yang W, Huang Q, Schnabl B, Chang P, Billiar TR, Jiang Y, Chen P. Intestinal microbiota mediates the susceptibility to polymicrobial sepsis-induced liver injury by granisetron generation in mice. Hepatology. 2019; 69(4):1751-1767. PMID: 30506577
  71. Lee KC, Chen P, Maricic I, Inamine T, Hu J, Gong S, Sun JC, Dasgupta S, Lin HC, Lin YT, Loomba R, Stärkel P, Kumar V, Schnabl B. Intestinal iNKT Cells Migrate to Liver and Contribute to Hepatocyte Apoptosis During Alcoholic Liver Disease. Am J Physiol Gastrointest Liver Physiol. 2019; 316(5):G585-G597. PMCID: PMC6580241
  72. Fu T, Coulter S, Yoshihara E, Oh TG, Fang S, Cayabyab F, Zhu Q, Zhang T, Leblanc M, Liu S, He M, Waizenegger W, Gasser E, Schnabl B, Atkins AR, Yu RT, Knight R, Liddle C, Downes M, Evans RM. FXR Regulates Intestinal Cancer Stem Cell Proliferation. Cell. 2019; 176(5):1098-1112. PMCID: PMC6701863
  73. Gao B, Lang S, Duan Y, Wang Y, Shawcross DL, Louvet A, Mathurin P, Ho SB, Stärkel P, Schnabl B. Serum and fecal oxylipins in patients with alcohol-related liver disease. Dig Dis Sci. 2019; 64(7):1878-1892. PMCID: PMC6588282
  74. Stärkel P, Schnabl B, Leclercq S, Komuta M, Bataller R, Argemi J, Palma E, Chokshi S, Hellerbrand C, Maccioni L, Lanthier N, Leclercq I. Deficient IL-6/Stat3 Signaling, High TLR7, and Type I Interferons in Early Human Alcoholic Liver Disease: A Triad for Liver Damage and Fibrosis. Hepatology Commun. 2019; 3(7):867-882. PMCID: PMC6601428
  75. Wang L, Mazagova M, Pan C, Yang S, Brandl K, Liu J, Reilly SM, Wang Y, Miao Z, Loomba R, Lu N, Guo Q, Liu J, Yu RT, Downes M, Evans RM, Brenner DA, Saltiel AR, Beutler B, Schnabl B. YIPF6 Controls Sorting of FGF21 Into COPII Vesicles and Promotes Obesity. Proc Natl Acad Sci U S A. 2019; 116(30):15184-15193. PMCID: PMC6660779
  76. Duan Y, Llorente C, Lang S, Brandl K, Chu H, Jiang L, White RC, Clarke TH, Nguyen K, Torralba M, Shao Y, Liu J, Hernandez-Morales A, Lessor L, Rahman IR, Miyamoto Y, Ly M, Gao B, Sun W, Kiesel R, Hutmacher F, Lee S, Ventura-Cots M, Bosques-Padilla F, Verna EC, Abraldes JG, Brown RS Jr, Vargas V, Altamirano J, Caballería J, Shawcross DL, Ho SB, Louvet A, Lucey MR, Mathurin P, Garcia-Tsao G, Bataller R, Tu XM, Eckmann L, van der Donk WA, Young R, Lawley TD, Stärkel P, Pride D, Fouts DE, Schnabl B. Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease. Nature. 2019, 575(7783):505-511. PMCID: PMC6872939
  77. Bluemel S, Wang L, Kuelbs C, Moncera K, Torralba M, Singh H, Fouts DE, Schnabl B. Intestinal and hepatic microbiota changes associated with chronic ethanol administration in mice. Gut Microbes. 2020; 11(3):265-275. PMCID: PMC7524386
  78. Lang S, Duan Y, Liu J, Torralba MG, Kuelbs C, Ventura-Cots M, Abraldes JG, Bosques-Padilla F, Verna EC, Brown RS Jr., Vargas V, Altamirano J, Caballería J, Shawcross D, Lucey MR, Louvet A, Mathurin P, Garcia-Tsao G, Ho SB, Tu XM, Bataller R, Stärkel P, Fouts DE, Schnabl B. Intestinal fungal dysbiosis and systemic immune response to fungi in patients with alcoholic hepatitis. Hepatology. 2020; 71(2):522-538. PMCID: PMC6925657
  79. Chu H, Duan Y, Lang S, Jiang L, Wang Y, Llorente C, Liu J, Mogavero S, Bosques-Padilla F, Abraldes JG, Vargas V, Tu XM, Yang L, Hou X, Hube B, Stärkel P, Schnabl B. The Candida albicans exotoxin Candidalysin promotes alcohol-associated liver disease. J Hepatol. 2020; 72(3):391-400. PMCID: PMC7031049
  80. Furuya S, Argemi J, Uehara T, Katou Y, Fouts DE, Schnabl B, Dubuquoy L, Belorkar A, Vadigepalli R, Kono H, Bataller R, Rusyn I. A novel mouse model of acute-on-chronic cholestatic alcoholic liver disease: A systems biology comparison with human alcoholic hepatitis. Alcohol Clin Exp Res. 2020; 44(1):87-101. PMCID: PMC6980964
  81. Lang S, Demir M, Duan Y, Martin A, Schnabl B. Cytolysin-positive Enterococcus faecalis is not increased in patients with non-alcoholic steatohepatitis. Liver Int. 2020; 40(4):860-865. PMCID: PMC8026328
  82. Bajic D, Niemann A, Hillmer AK, Mejias-Luque R, Bluemel S, Docampo M, Funk MC, Tonin E, Boutros M, Schnabl B, Busch DH, Miki T, Schmid RM, van den Brink MRM, Gerhard M, Stein-Thoeringer CK. Gut microbiota derived propionate regulates the expression of Reg3 mucosal lectins and ameliorates experimental colitis in mice. J Crohns and Colitis. 2020; 14(10):1462-1472. PMCID: PMC8921751
  83. Lang S, Martin A, Farowski F, Wisplinghoff H, Vehreschild MJGT, Liu J, Krawczyk M, Nowag A, Kretzschmar A, Herweg J, Schnabl B, Tu XM, Lammert F, Goeser T, Tacke F, Heinzer K, Kasper P, Steffen HM, Demir M. High protein intake is associated with histological disease activity in patients with NAFLD. Hepatology Commun. 2020; 4(5):681-695. PMCID: PMC7193126
  84. Marrero I, Maricic I, Morgan TR, Stolz AA, Schnabl B, Liu ZX, Tsukamoto H, Kumar V. Differential activation of unconventional T cells, including iNKT cells, in alcohol-related liver disease. Alcohol Clin Exp Res. 2020; 44(5):1061-1074. PMCID: PMC7211132
  85. Gao B, Emami A, Zhou R, Lang S, Duan Y, Wang Y, Jiang L, Loomba R, Brenner DA, Stärkel P, Schnabl B. Functional Microbial Responses to Alcohol Abstinence in Patients With Alcohol Use Disorder. Front Physiol. 2020; 11:370. PMCID: PMC7193112
  86. Gao B, Duan Y, Lang S, Barupal D, Wu TC, Valdiviez L, Roberts B, Choy YY, Shen T, Byram G, Zhang Y, Fan S, Wancewicz B, Shao Y, Vervier K, Wang Y, Zhou R, Jiang L, Nath S, Loomba R, Abraldes JG, Bataller R, Tu XM, Stärkel P, Lawley TD, Fiehn O, Schnabl B. Functional microbiomics reveals alterations of the gut microbiome and host co-metabolism in alcoholic hepatitis patients. Hepatology Commun. 2020; 4(8):1168-1182. PMCID: PMC7395072
  87. Chu H, Jiang L, Gao B, Gautam N, Alamoudi JA, Lang S, Wang Y, Duan Y, Alnouti Y, Cable EE, Schnabl B. The selective PPAR-delta agonist seladelpar reduces ethanol-induced liver disease by restoring gut barrier function and bile acid homeostasis in mice. Transl Res. 2020: S1931-5244(20)30143-2. PMCID: PMC7719076
  88. Maccioni L, Gao B, Leclercq S, Pirlot B, Horsmans Y, De Timary P, Leclercq I, Fouts DE, Schnabl B, Stärkel P. Intestinal permeability, microbial translocation, changes in duodenal and fecal microbiota, and their associations with alcoholic liver disease progression in humans. Gut Microbes. 2020; 12(1):1782157. PMCID: PMC7524402
  89. Lang S, Fairfied B, Gao B, Duan Y, Zhang X, Fouts DE, Schnabl B. Changes in the fecal bacterial microbiota associated with disease severity in alcoholic hepatitis patients. Gut Microbes. 2020; 12(1):1785251. PMCID: PMC7524371
  90. Bluemel S, Wang Y, Lee S, Schnabl B. Tumor necrosis factor alpha receptor 1 deficiency in hepatocytes does not protect from non-alcoholic steatohepatitis, but attenuates insulin resistance in mice. World J Gastroenterol. 2020; 26(33):4933-4944. PMCID: PMC7476178
  91. Zhou R, Llorente C, Cao J, Gao B, Duan Y, Jiang L, Wang Y, Kumar V, Stärkel P, Bode L, Fan X, Schnabl B. Deficiency of Intestinal α1-2-Fucosylation Exacerbates Ethanol-Induced Liver Disease in Mice. Alcohol Clin Exp Res. 2020; 44(9):1842-1851. PMCID: PMC7808344
  92. Jiang L, Chu H, Gao B, Lang S, Wang Y, Duan Y, Schnabl B. Transcriptomic Profiling Identifies Novel Hepatic and Intestinal Genes Following Chronic Plus Binge Ethanol Feeding in Mice. Dig Dis Sci. 2020; 65(12):3592-3604. PMCID: PMC7669632
  93. Lang S, Demir M, Martin A, Jiang L, Zhang X, Duan Y, Gao B, Wisplinghoff H, Kasper P, Roderburg C, Tacke F, Steffen HM, Goeser T, Abraldes JG, Tu XM, Loomba R, Stärkel P, Pride D, Fouts DE, Schnabl B. Intestinal Virome Signature Associated With Severity of Nonalcoholic Fatty Liver Disease. Gastroenterology. 2020; 159(5):1839-1852. PMCID: PMC8404510
  94. Chu H, Bai T, Chen L, Hu L, Xiao L, Yao L, Zhu R, Niu X, Li Z, Zhang L, Han C, Song S, He Q, Zhao Y, Zhu Q, Chen H, Schnabl B, Yang L, Hou X. Multicenter Analysis of Liver Injury Patterns and Mortality in COVID-19. Front Med (Lausanne). 2020; 20;7:584342. PMCID: PMC7606271
  95. Chu H, Li J, Yan J, Bai T, Schnabl B, Zou L, Yang L, Hou X. Persistent SARS-CoV-2 RNA Positive in Feces but Negative in Breastmilk: A Case Report of COVID-19 in a Breastfeeding Patient. Front Med (Lausanne). 2020; 7:562700. PMCID: PMC7738631
  96. Wang Z, Wang Y, Bradbury N, Gonzales Bravo C, Schnabl B, Di Nardo A. Skin wound closure delay in metabolic syndrome correlates with SCF deficiency in keratinocytes. Sci Rep. 2020; 10(1):21732. PMCID: PMC7728784
  97. Jiang L, Lang S, Duan Y, Zhang X, Gao B, Chopyk J, Schwanemann LK, Ventura-Cots M, Bataller R, Bosques-Padilla F, Verna EC, Abraldes JG, Brown RS Jr, Vargas V, Altamirano J, Caballería J, Shawcross DL, Ho SB, Louvet A, Lucey MR, Mathurin P, Garcia-Tsao G, Kisseleva T, Brenner DA, Tu XM, Stärkel P, Pride D, Fouts DE, Schnabl B. Intestinal virome in patients with alcoholic hepatitis. Hepatology. 2020; 72(6):2182-2196. PMCID: PMC8159727
  98. Zhang Q, Ma C, Duan Y, Heinrich B, Rosato U, Diggs LP, Ma L, Roy S, Fu Q, Brown Z, Wabitsch S, Thovarai V, Fu J, Feng D, Ruf B, Cui L, Subramanyam V, Frank KM, Wang S, Kleiner DE, Ritz T, Rupp C, Gao B, Longerich T, Wang XW, Korangy F, Kroemer A, Schnabl B, Trinchieri G, Greten TF. Gut microbiome directs hepatocytes to recruit MDSCs and promote cholangiocarcinoma. Cancer Discovery. 2021; 11(5):1248-1267. PMCID: PMC8102309
  99. Gao B, Zhang X, Schnabl B. Fungi-bacteria correlation in alcoholic hepatitis patients. Toxins. 2021; 13(2):143. PMCID: PMC8102309
  100. Zhou R, Llorente C, Cao J, Zaramela LS, Zeng S, Gao B, Li S, Welch RD, Huang FQ, Qi LW, Pan C, Huang Y, Zhou P, Beussen I, Zhang Y, Bryam G, Fiehn O, Wang L, Liu EH, Yu RT, Downes M, Evans RM, Goglin K, Fouts DE, Brenner DA, Bode L, Fan X, Zengler K, Schnabl B. Intestinal α1-2-fucosylation contributes to obesity and steatohepatitis in mice. Cell Mol Gastroenterol Hepatol. 2021; 12(1):293-320. PMCID: PMC8166943
  101. Gao B, Argemi J, Bataller R, Schnabl B. Serum Acylcarnitines Associated with High Short-Term Mortality in Patients with Alcoholic Hepatitis. Biomolecules. 2021; 11(2):281. PMCID: PMC7917657
  102. Hsieh YC, Lee KC, Lei HJ, Lan KH, Huo TI, Lin YT, Chan CC, Schnabl B, Huang YH, Hou MC, Lin HC. (Pro)renin Receptor Knockdown Attenuates Liver Fibrosis Through Inactivation of ERK/TGF-β1/SMAD3 Pathway. Cell Mol Gastroenterol Hepatol. 2021;12(3):813-838. PMCID: PMC8340309
  103. Cabré N, Duan Y, Llorente C, Conrad M, Stern P, Yamashita D, Schnabl B. Colesevelam Reduces Ethanol-Induced Liver Steatosis in Humanized Gnotobiotic Mice. Cells. 2021; 10(6):1496. PMCID: PMC8232222
  104. Hartmann P, Lang S, Zeng S, Duan Y, Zhang X, Wang Y, Bondareva M, Kruglov A, Fouts DE, Stärkel P, Schnabl B. Dynamic Changes of the Fungal Microbiome in Alcohol Use Disorder. Front Physiol. 2021; 12:699253. PMCID: PMC8327211
  105. Ganguly S, Muench GA, Shang L, Rosenthal SB, Rahman G, Wang R, Wang Y, Kwon HC, Diomino AM, Kisseleva T, Soorosh P, Hosseini M, Knight R, Schnabl B, Brenner DA, Dhar D. Nonalcoholic Steatohepatitis and HCC in a Hyperphagic Mouse Accelerated by Western Diet. Cell Mol Gastroenterol Hepatol. 2021; 12(3):891-920. PMCID: PMC8342972
  106. Lang S, Martin A, Zhang X, Farowski F, Wisplinghoff H, J G T Vehreschild M, Krawczyk M, Nowag A, Kretzschmar A, Scholz C, Kasper P, Roderburg C, Mohr R, Lammert F, Tacke F, Schnabl B, Goeser T, Steffen HM, Demir M. Combined analysis of gut microbiota, diet and PNPLA3 polymorphism in biopsy-proven non-alcoholic fatty liver disease. Liver Int. 2021; 41(7):1576-1591. PMCID: PMC8947846
  107. Liu J, Zhang X, Chen T, Wu T, Lin T, Jiang L, Lang S, Liu L, Natarajan L, Tu JX, Kosciolek T, Morton J, Nguyen TT, Schnabl B, Knight R, Feng C, Zhong Y, Tu XM. A semiparametric model for between-subject attributes: Applications to beta-diversity of microbiome data. Biometrics. 2021; 10.1111/biom.13487. PMCID: PMC8602427
  108. Duan Y, Chu H, Brandl K, Jiang L, Zeng S, Meshgin N, Papachristoforou E, Argemi J, Mendes BG, Wang Y, Su H, Sun W, Llorente C, Hendrikx T, Liu X, Hosseini M, Kisseleva T, Brenner DA, Bataller R, Ramachandran P, Karin M, Fu W, Schnabl B. CRIg on liver macrophages clears pathobionts and protects against alcoholic liver disease. Nat Commun. 2021; 12(1):7172. PMCID: PMC8660815
  109. Gao B, Zhu Y, Gao N, Shen W, Stärkel P, Schnabl B. Integrative Analysis of Metabolome and Microbiome in Patients with Progressive Alcohol-Associated Liver Disease. Metabolites. 2021; 11(11):766. PMCID: PMC8621614
  110. Qian M, Liu J, Zhao D, Cai P, Pan C, Jia W, Gao Y, Zhang Y, Zhang N, Zhang Y, Zhang Q, Wu D, Shan C, Zhang M, Schnabl B, Yang S, Shen X, Wang L. Aryl Hydrocarbon Receptor Deficiency in Intestinal Epithelial Cells Aggravates Alcohol-Related Liver Disease. Cell Mol Gastroenterol Hepatol. 2022; 13(1):233-256. PMCID: PMC8599170
  111. Musto JA, Eickhoff J, Ventura-Cots M, Abraldes JG, Bosques-Padilla F, Verna EC, Brown RS Jr, Vargas V, Altamirano J, Caballería J, Shawcross D, Louvet A, Mathurin P, Garcia-Tsao G, Schnabl B, Bataller R, Lucey MR. The Level of Alcohol Consumption in the Prior Year Does Not Impact Clinical Outcomes in Patients With Alcohol-Associated Hepatitis. Liver Transpl. 2021; 27(10):1382-1391. PMID: 34109723
  112. Demir M*, Lang S*, Hartmann P*, Duan Y, Martin A, Miyamoto Y, Bondareva M, Zhang X, Wang Y, Kasper P, Bang C, Roderburg C, Tacke F, Steffen HM, Goeser T, Kruglov A, Eckmann L, Stärkel P, Fouts DE, Schnabl B. The fecal mycobiome in non-alcoholic fatty liver disease. J Hepatol. 2022; 76(4):788-799. PMCID: PMC8981795
  113. Parker R, Cabezas J, Altamirano J, Arab JP, Ventura-Cots M, Sinha A, Dhanda A, Arrese M, McCune CA, Rowe IA, Schnabl B, Mathurin P, Shawcross D, Abraldes JG, Lucey MR, Garcia-Tsao G, Verna E, Brown RS Jr, Bosques-Padilla F, Vargas V, Louvet A, Holt AP, Bataller R. Trajectory of Serum Bilirubin Predicts Spontaneous Recovery in a Real-World Cohort of Patients With Alcoholic Hepatitis. Clin Gastroenterol Hepatol. 2022; 20(2):e289-e297. PMCID: PMC9188123
  114. Staudacher JJ, Bauer J, Atkinson SR, Thursz M, Lang S, Schnabl B, Wiley MB, Carr R, Jung B. Systemic Activin Is Elevated in Patients With Severe Alcoholic Hepatitis. Gastro Hep Adv. 2022; 1(2):147-149. PMCID: PMC9119346
  115. Ventura-Cots M, Argemi J, Jones PD, Lackner C, El Hag M, Abraldes JG, Alvarado E, Clemente A, Ravi S, Alves A, Alboraie M, Altamirano J, Barace S, Bosques F, Brown R, Caballeria J, Cabezas J, Carvalhana S, Cortez-Pinto H, Costa A, Degré D, Fernandez-Carrillo C, Ganne-Carrie N, Garcia-Tsao G, Genesca J, Koskinas J, Lanthier N, Louvet A, Lozano JJ, Lucey MR, Masson S, Mathurin P, Mendez-Sanchez N, Miquel R, Moreno C, Mounajjed T, Odena G, Kim W, Sancho-Bru P, Warren Sands R, Szafranska J, Verset L, Schnabl B, Sempoux C, Shah V, Shawcross DL, Stauber RE, Straub BK, Verna E, Tiniakos D, Trépo E, Vargas V, Villanueva C, Woosley JT, Ziol M, Mueller S, Stärkel P, Bataller R. Clinical, histological and molecular profiling of different stages of alcohol-related liver disease. Gut. 2022; 71(9):1856-1866. PMID: 34992134.
  116. Hartmann P, Duan Y, Miyamoto Y, Demir M, Lang S, Hasa E, Stern P, Yamashita D, Conrad M, Eckmann L, Schnabl B. Colesevelam ameliorates non-alcoholic steatohepatitis and obesity in mice. Hepatol Int. 2022; 16(2):359-370. PMCID: PMC9013343
  117. Gao B, Wu TC, Lang S, Jiang L, Duan Y, Fouts DE, Zhang X, Tu XM, Schnabl B. Machine Learning Applied to Omics Datasets Predicts Mortality in Patients with Alcoholic Hepatitis. Metabolites. 2022; 12(1):41. PMCID: PMC8781791
  118. Czernuszewicz TJ, Aji AM, Moore CJ, Montgomery SA, Velasco B, Torres G, Anand KS, Johnson KA, Deal AM, Zukić D, McCormick M, Schnabl B, Gallippi CM, Dayton PA, Gessner RC. Development of a Robotic Shear Wave Elastography System for Noninvasive Staging of Liver Disease in Murine Models. Hepatol Commun. 2022; 6(7):1827-1839. PMCID: PMC9234684
  119. Jiménez C, Ventura-Cots M, Sala M, Calafat M, Garcia-Retortillo M, Cirera I, Cañete N, Soriano G, Poca M, Simón-Talero M, Altamirano J, Lucey M, Garcia-Tsao G, Brown RS Jr, Schwabe RF, Verna EC, Schnabl B, Bosques-Padilla F, Mathurin P, Caballería J, Louvet A, Shawcross DL, Abraldes JG, Genescà J, Bataller R, Vargas V. Effect of rifaximin on infections, acute-on-chronic liver failure and mortality in alcoholic hepatitis: A pilot study (RIFA-AH). Liver Int. 2022; 42(5):1109-1120. PMCID: PMC9311407
  120. Ma S, Patel SA, Abe Y, Chen N, Patel PR, Cho BS, Abbasi N, Zeng S, Schnabl B, Chang JT, Huang WJM. RORγt phosphorylation protects against T cell-mediated inflammation. Cell Rep. 2022; 38(11):110520. PMCID: PMC8982147
  121. Mendes BG, Duan Y, Schnabl B. Immune Response of an Oral Enterococcus faecalisPhage Cocktail in a Mouse Model of Ethanol-Induced Liver Disease. Viruses. 2022; 14(3):490. PMCID: PMC8955932
  122. Hsu CL, Zhang X, Jiang L, Lang S, Hartmann P, Pride D, Fouts DE, Stärkel P, Schnabl B. Intestinal virome in patients with alcohol use disorder and after abstinence. Hepatol Commun. 2022; 6(8):2058-2069. PMCID: PMC9315129
  123. Gao B, Zeng S, Maccioni L, Shi X, Armando A, Quehenberger O, Zhang X, Stärkel P#, Schnabl B#. Lipidomics for the Prediction of Progressive Liver Disease in Patients with Alcohol Use Disorder. Metabolites. 2022; 12(5):433. PMCID: PMC9146183
  124. Kouno T, Liu X, Zhao H, Kisseleva T, Cable EE, Schnabl B. Selective PPARδ agonist seladelpar suppresses bile acid synthesis by reducing hepatocyte CYP7A1 via the fibroblast growth factor 21 signaling pathway. J Biol Chem. 2022; 298(7):102056. PMCID: PMC9214809
  125. Martino C*, Zaramela LS*, Gao B*, Embree M, Tarasova J, Parker SJ, Wang Y, Chu H, Chen P, Lee KC, Galzerani DD, Gengatharan JM, Lekbua A, Neal M, Knight R, Tsukamoto H, Metallo CM, Schnabl B#, Zengler K#. Acetate reprograms gut microbiota during alcohol consumption. Nat Commun. 2022; 13(1):4630. PMCID: PMC9359997
  126. Maccioni L, Loriot A, Dewulf J, Bommer G, Horsmans Y, Lanthier N, Leclercq I, Schnabl B, Stärkel P. Duodenal CD8+ T resident memory cell apoptosis contributes to gut barrier dysfunction and microbial translocation in early alcohol-associated liver disease in humans. Aliment Pharmacol Ther. 2022; 56(6):1055-1070. PMCID: PMC9398988
  127. Hartmann P, Schnabl B. Inexpensive, Accurate, and Stable Method to Quantitate Blood Alanine Aminotransferase (ALT) Levels. Methods Protoc. 2022; 5(5):81. PMCID: PMC9610295
  128. Lee PC, Lee KC, Yang TC, Lu HS, Cheng TY, Chen YJ, Chiou JJ, Huang CW, Yang UC, Chia-Hui Tan E, Chou SH, Kuo YL, Schnabl B, Huang YH, Hou MC. Sarcopenia-related gut microbial changes are associated with the risk of complications in people with cirrhosis. JHEP Rep. 2022; 5(1):100619. PMCID: PMC9758430
  129. Zeng S, Hartmann P, Park M, Duan Y, Lang S, Llorente C, Wang Y, Cabré N, Fouts DE, Bacher P, Jung WH, Stärkel P, Schnabl B. Malassezia restricta promotes alcohol-induced liver injury. Hepatol Commun. 2023; 7(2):e0029. PMCID: PMC9988279
  130. Gao B, Zhu Y, Shen W, Stärkel P, Schnabl B. Correlation between Serum Steroid Hormones and Gut Microbiota in Patients with Alcohol-Associated Liver Disease. Metabolites. 2022; 12(11):0. PMCID: PMC9699110
  131. Hsu CL, Lang S, Demir M, Fouts DE, Stärkel P, Schnabl B. Any alcohol use in NAFLD patients is associated with significant changes to the intestinal virome. Hepatology. 2023; 77(6):2073-2083. PMCID: PMC10192041
  132. Hendrikx T, Lang S, Rajcic D, Wang Y, McArdle S, Kim K, Mikulski Z, Schnabl B. Hepatic pIgR-mediated secretion of IgA limits bacterial translocation and prevents ethanol-induced liver disease in mice. Gut. 2023; 72(10):1959-1970. PMCID: PMC10841342
  133. Cabré N*, Hartmann P*, Llorente C, Kouno T, Wang Y, Zeng S, Kim HY, Zhang X, Kisseleva T, Iyer S, Kudumala S, Schnabl B. IgY antibodies against cytolysin reduce ethanol-induced liver disease in mice. Hepatology. 2023; 78(1):295-306. PMCID: PMC10293100
  134. Zeng S, Rosati E, Saggau C, Messner B, Chu H, Duan Y, Hartmann P, Wang Y, Ma S, Huang WJM, Lee J, Lee SM, Carvalho-Gontijo R, Zhang V, Hoffmann JP, Kolls JK, Raz E, Brenner DA, Kisseleva T, LeibundGut-Landmann S, Bacher P, Stärkel P, Schnabl B. Candida albicans-specific Th17 cell-mediated response contributes to alcohol-associated liver disease. Cell Host Microbe. 2023; 31(3):389-404. PMCID: PMC10039706
  135. Maccioni L, Kasavuli J, Leclercq S, Pirlot B, Laloux G, Horsmans Y, Leclercq I, Schnabl B, Stärkel P. Toll-like receptor 2 activation in monocytes contributes to systemic inflammation and alcohol-associated liver disease in humans. Hepatol Commun. 2023; 7(5):e0107. PMCID: PMC10109139
  136. Hsu CL, Wang Y, Duan Y, Chu H, Hartmann P, Llorente C, Zhou R, Schnabl B. Differences in Bacterial Translocation and Liver Injury in Ethanol Versus Diet-Induced Liver Disease. Dig Dis Sci. 2023; 68(7):3059-3069. PMCID: PMC10313731
  137. Kouno T, Zeng S, Wang Y, Duan Y, Lang S, Gao B, Hartmann P, Cabré N, Llorente C, Galbert C, Emond P, Sokol H, James M, Chao CC, Gao JR, Perreault M, Hava DL, Schnabl B. Engineered bacteria producing aryl-hydrocarbon receptor agonists protect against ethanol-induced liver disease in mice. Alcohol Clin Exp Res (Hoboken). 2023; 47(5):856-867. PMCID: PMC10795770
  138. Hartmann P, Zhang X, Loomba R, Schnabl B. Global and national prevalence of nonalcoholic fatty liver disease in adolescents: An analysis of the global burden of disease study 2019. Hepatology. 2023; 78(4):1168-1181. PMCID: PMC10521800
  139. Maccioni L, Horsmans Y, Leclercq I, Schnabl B, Stärkel P. Serum keratin 18-M65 levels detect progressive forms of alcohol-associated liver disease in early noncirrhotic stages. Alcohol Clin Exp Res (Hoboken). 2023; 47(6):1079-1087. PMCID: PMC10803128
  140. Hartmann P, Lang S, Schierwagen R, Klein S, Praktiknjo M, Trebicka J, Schnabl B. Fecal cytolysin does not predict disease severity in acutely decompensated cirrhosis and acute-on-chronic liver failure. Hepatobiliary Pancreat Dis Int. 2023; 22(5):474-481. PMCID: PMC10797562
  141. Borin JM, Liu R, Wang Y, Wu TC, Chopyk J, Huang L, Kuo P, Ghose C, Meyer JR, Tu XM, Schnabl B, Pride DT. Fecal virome transplantation is sufficient to alter fecal microbiota and drive lean and obese body phenotypes in mice. Gut Microbes. 2023; 15(1):2236750. PMCID: PMC10364654
  142. Gu P, Liu R, Yang Q, Xie L, Wei R, Li J, Mei F, Chen T, Zeng Z, He Y, Zhou H, Peng H, Nandakumar KS, Chu H, Jiang Y, Gong W, Chen Y, Schnabl B, Chen P. A metabolite from commensal Candida albicans enhances the bactericidal activity of macrophages and protects against sepsis. Cell Mol Immunol. 2023; 20(10):1156-1170. PMCID: PMC10541433
  143. Bennett H, Troutman TD, Zhou E, Spann NJ, Link VM, Seidman JS, Nickl CK, Abe Y, Sakai M, Pasillas MP, Marlman JM, Guzman C, Hosseini M, Schnabl B, Glass CK. Discrimination of cell-intrinsic and environment-dependent effects of natural genetic variation on Kupffer cell epigenomes and transcriptomes. Nat Immunol. 2023; 24(11):1825-1838. PMCID: PMC10602851
  144. Hernandez JE, Llorente C, Ma S, Miyamoto KT, Sinha S, Steele S, Xiao Z, Lai CJ, Zuniga EI, Ghosh P, Schnabl B, Huang WJM. The arginine methyltransferase PRMT5 promotes mucosal defense in the intestine. Life Sci Alliance. 2023; 6(11):e202302026. PMCID: PMC10477432
  145. Cabré N, Yang Y, Wang Y, Schnabl B. Development of a Quantitative PCR Method for Detecting Enterococcus faecalis Cytolysin in Human Stool Samples. Methods Protoc. 2023; 6(6):107. PMCID: PMC10660514
  146. Li D, Chen Y, Wan M, Mei F, Wang F, Gu P, Zhang X, Wei R, Zeng Y, Zheng H, Chen B, Xiong Q, Xue T, Guan T, Guo J, Tian Y, Zeng LY, Liu Z, Yuan H, Yang L, Liu H, Dai L, Yu Y, Qiu Y, Wu P, Win S, Than TA, Wei R, Schnabl B, Kaplowitz N, Jiang Y, Ma Q, Chen P. Oral magnesium prevents acetaminophen-induced acute liver injury by modulating microbial metabolism. Cell Host Microbe. 2024; 32(1):48-62. PMID: 38056458.
  147. Viebahn G*, Hartmann P*, Lang S, Demir M, Zhang X, Fouts DE, Stärkel P, Schnabl B. Fungal signature differentiates alcohol-associated liver disease from nonalcoholic fatty liver disease. Gut Microbes. 2024; 16(1):2307586. PMCID: PMC10841010.
  148. Yamazaki T, Kouno T, Hsu CL, Hartmann P, Mayo S, Zhang X, Stärkel P, Bosques-Padilla F, Verna EC, Abraldes JG, Brown RS Jr, Vargas V, Altamirano J, Caballería J, Shawcross DL, Louvet A, Lucey MR, Mathurin P, Garcia-Tsao G, Bataller R, Schnabl B; AlcHepNet Investigators. Serum aryl hydrocarbon receptor activity is associated with survival in patients with alcohol-associated hepatitis. Hepatology. 2024; 80(2):403-417. PMCID: PMC11268475.
  149. Al-Karaghouli M, Ventura-Cots M, Wong YJ, Genesca J, Bosques F, Brown RS Jr, Mathurin P, Louvet A, Shawcross D, Vargas V, Verna EC, Schnabl B, Caballeria J, Shah VJ, Kamath PS, Lucey MR, Garcia-Tsao G, Bataller R, Abraldes JG. Relationship between updated MELD and prognosis in alcohol-associated hepatitis: Opportunities for more efficient trial design. Hepatol Commun. 2024; 8(8):e0495. PMID: 39082963
  150. Hsu CL, Wang L, Maestri E, Jacob AR, Mayo S, Bosques-PadillaF, Verna EC, Abraldes JC, Brown Jr RS, Vargas V, Altamirano J, Caballería J, Shawcross DL, Louvet A, Lucey MR, Mathurin P, Garcia-Tsao G, Stärkel P, Bataller R, AlcHepNet Investigators, Wang XW, Schnabl B. Viral antibody response predicts morbidity and mortality in alcohol-associated hepatitis. Hepatology. 2024; accepted. PMID: 39325984
  151. Kreimeyer H, Gonzalez CG, Fondevila MF, Hsu CL, Hartmann P, Zhang X, Stärkel P, Bosques-Padilla F, Verna EC, Abraldes JG, Brown RS Jr, Vargas V, Altamirano J, Caballería J, Shawcross DL, Louvet A, Lucey MR, Mathurin P, Garcia-Tsao G, Bataller R, Investigators A, Gonzalez DJ, Schnabl B. Faecal proteomics links neutrophil degranulation with mortality in patients with alcohol-associated hepatitis. Gut. 2024; 74(1):103-115. PMCID: PMC11631684
  152. Yang AH, Tincopa MA, Tavaglione F, Ajmera VH, Richards LM, Amangurbanova M, Butcher C, Hernandez C, Madamba E, Singh S, Bettencourt R, Schnabl B, Sirlin CB, Loomba R. Prevalence of steatotic liver disease, advanced fibrosis and cirrhosis among community-dwelling overweight and obese individuals in the USA. Gut. 2024; 73(12):2045-2053. PMID: 39117370
  153. Yang Y*, Hartmann P*, Schnabl B. Fecal gelatinase does not predict mortality in patients with alcohol-associated hepatitis. Microb Cell. 2024; 11:328-338. PMCID: PMC11350238
  154. Zhang P, Liu J, Lee A, Tsaur I, Ohira M, Duong V, Vo N, Watari K, Su H, Kim JY, Gu L, Zhu M, Shalapour S, Hosseini M, Bandyopadhyay G, Zeng S, Llorente C, Zhao HN, Lamichhane S, Mohan S, Dorrestein PC, Olefsky JM, Schnabl B, Soroosh P, Karin M. IL-22 resolves MASLD via enterocyte STAT3 restoration of diet-perturbed intestinal homeostasis. Cell Metab. 2024; 36(10):2341-2354. PMCID: PMC11631175
  155. Czernuszewicz TJ, Wang Y, Jiang L, Kim K, Mikulski Z, Aji AM, Rojas JD, Gessner RC, Schnabl B. Noninvasive Monitoring of Steatotic Liver Disease in Western Diet-Fed Obese Mice Using Automated Ultrasound and Shear Wave Elastography. Liver Int. 2024. PMID: 39523997
  156. Gao W, Wang G, Yuan H, Chen Y, Che J, Cheng Z, Chen L, Zhang L, Zhu Y, Liu X, Liu A, Yang Q, Cao P, Qian W, Huang W, Schnabl B, Yang L, Chu H. Gram-positive probiotics improves acetaminophen-induced hepatotoxicity by inhibiting leucine and Hippo-YAP pathway. Cell Biosci. 2025 ;15(1): 32. PMCID: PMC11887100.
  157. Özdirik B, Berger H, Tonetti FR, Cabré N, Treichel N, Clavel T, Tacke F, Sigal M, Schnabl B. Faecal Cytolysin is Associated With Worse Survival in Patients With Primary Sclerosing Cholangitis. Liver Int. 2025; 45(4):e16181. PMID: 40083245.
  158. Fujiki J, Nakamura T, Kreimeyer H, Llorente C, Fouts DE, Schnabl B. Insertion sequence-mediated phage resistance contributes to attenuated colonization of cytolytic Enterococcus faecalis variants in the gut. Microbiol Spectr. 2025; 13(5):e0330324. PMCID: PMC12054073
  159. Münte E, Viebahn G, Khurana A, Fujiki J, Nakamura T, Lang S, Demir M, Schnabl B, Hartmann P. Faecalibacterium prausnitzii Is Associated with Disease Severity in MASLD but Its Supplementation Does Not Improve Diet-Induced Steatohepatitis in Mice. Microorganisms. 2025; 13(3):675. PMCID: PMC11944644
  160. Wu PS, Lee PC, Chang TE, Hsieh YC, Huang CW, Lin CH, Huang YL, Lin YT, Huo TI, Schnabl B, Lee KC, Hou MC. Fecal carriage of multidrug-resistant organisms increases the risk of hepatic encephalopathy in patients with cirrhosis: insights from gut microbiota and metabolite features. Gut Pathog. 2025; 17(1):30. PMCID: PMC12085042
  161. Kreimeyer H, Sydor S, Buchholz L, Toskal C, Özcürümez M, Schnabl B, Syn WK, Sowa JP, Manka P, Canbay A. Non-Alcoholic Beer Influences Glucose and Lipid Metabolism and Changes Body Composition in Healthy, Young, Male Adults. Nutrients. 2025; 17(10):1625. PMCID: PMC12114185
  162. Yang Y*, Duan Y*, Lang S*, Fondevila MF, Schöler D, Harberts A, Cabré N, Chen S, Shao Y, Vervier K, Miyamoto Y, Zhang X, Chu H, Yang L, Tan C, Eckmann L, Bosques-Padilla F, Verna EC, Abraldes JG, Brown RS Jr, Vargas V, Altamirano J, Caballería J, Shawcross DL, Louvet A, Lucey MR, Mathurin P, Garcia-Tsao G, Bataller R, Stärkel P, Lawley TD, Schnabl B. Targeted inhibition of pathobiont virulence factor mitigates alcohol-associated liver disease. Cell Host Microbe. 2025; 33(6):957-972. PMCID: PMC12162233
  163. Cabré N*, Fondevila MF*, Wei W, Yamazaki T, Tonetti FR, Eguileor A, Garcia-Carbonell R, Meijnikman AS, Miyamoto Y, Mayo S, Wang Y, Zhang X, Trimbuch T, Lehnardt S, Eckmann L, Fouts DE, Llorente C, Tsukamoto H, Stärkel P, Schnabl B. Activation of intestinal endogenous retroviruses by alcohol exacerbates liver disease. J Clin Invest. 2025; 135(13):e188541PMCID: PMC12208555
  164. Li J, Xie S, Chen M, Hong C, Chen Y, Lyu F, Tang N, Chen T, Zhao L, Zou W, Peng H, Bao J, Gu P, Schnabl B, Chen J, Chen P. Panose prevents acute-on-chronic liver failure by reducing bacterial infection in mice. J Clin Invest. 2025, accepted. PMID: 40478727

*shared first author, #shared last and corresponding author

Work as part of a consortium or acknowledged contributor

  1. Tu W, Gawrieh S, Dasarathy S, Mitchell MC, Simonetto DA, Patidar KR, McClain CJ, Bataller R, Szabo G, Tang Q, Barton BA, Radaeva S, Sanyal AJ, Shah V; Alcoholic Hepatitis Network (AlcHepNet) Investigators (including Schnabl B). Design of a multicenter randomized clinical trial for treatment of Alcohol-Associated Hepatitis. Contemp Clin Trials Commun. 2023; 32:101074. PMCID: PMC9869411
  2. Kaffe E, Roulis M, Zhao J, Qu R, Sefik E, Mirza H, Zhou J, Zheng Y, Charkoftaki G, Vasiliou V, Vatner DF, Mehal WZ; AlcHepNet (including Schnabl B); Yuval Kluger, Flavell RA. Humanized mouse liver reveals endothelial control of essential hepatic metabolic functions. Cell. 2023; 186(18):3793-3809. PMCID: PMC10544749
  3. Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, Romero D, Abdelmalek MF, Anstee QM, Arab JP, Arrese M, Bataller R, Beuers U, Boursier J, Bugianesi E, Byrne CD, Castro Narro GE, Chowdhury A, Cortez-Pinto H, Cryer DR, Cusi K, El-Kassas M, Klein S, Eskridge W, Fan J, Gawrieh S, Guy CD, Harrison SA, Kim SU, Koot BG, Korenjak M, Kowdley KV, Lacaille F, Loomba R, Mitchell-Thain R, Morgan TR, Powell EE, Roden M, Romero-Gómez M, Silva M, Singh SP, Sookoian SC, Spearman CW, Tiniakos D, Valenti L, Vos MB, Wong VW, Xanthakos S, Yilmaz Y, Younossi Z, Hobbs A, Villota-Rivas M, Newsome PN; NAFLD Nomenclature consensus group (including Schnabl B). A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023; 78(6):1966-1986. PMCID: PMC10653297
  4. Dasarathy S, Tu W, Bellar A, Welch N, Kettler C, Tang Q, Liangpunsakul S, Gawrieh S, Radaeva S, Mitchell M; AlcHepNet (including Schnabl B). Development and evaluation of objective trial performance metrics for multisite clinical studies: Experience from the AlcHep Network. Contemp Clin Trials. 2024; 138:107437. PMCID: PMC11866342
  5. Gawrieh S, Dasarathy S, Tu W, Kamath PS, Chalasani NP, McClain CJ, Bataller R, Szabo G, Tang Q, Radaeva S, Barton B, Nagy LE, Shah VH, Sanyal AJ, Mitchell MC; AlcHepNet Investigators (including Schnabl B). Randomized trial of anakinra plus zinc vs. prednisone for severe alcohol-associated hepatitis. J Hepatol. 2024; 80(5):684-693. PMCID: PMC11214682.
  6. Taiwo M, Huang E, Pathak V, Bellar A, Welch N, Dasarathy J, Streem D, McClain CJ, Mitchell MC, Barton BA, Szabo G, Dasarathy S; Alcohol Hepatitis Network (AlcHepNet) Consortium (including Schnabl B); Schaefer EA, Luther J, Day LZ, Ouyang X, Suyavaran A, Mehal WZ, Jacobs JM, Goodman RP, Rotroff DM, Nagy LE. Proteomics identifies complement protein signatures in patients with alcohol-associated hepatitis. JCI Insight. 2024; 9(9):e174127. PMCID: PMC11141929
  7. Patidar KR, Tu W, Cotter TG, Simonetto DA, Asgharpour A, Jan MY, Tang Q, Yu Y, Li Y, Taiwo M, Thevkar Nagesh P, Dasarathy S, Kamath PS, McClain CJ, Chalasani N, Szabo G, Bataller R, Mitchell M, Mehal WZ, Nagy LE, Shah VH, Gawrieh S, Sanyal AJ; AlcHepNet Investigators (including Schnabl B). Acute kidney injury in severe alcohol-associated hepatitis treated with anakinra plus zinc or prednisone. Hepatology. 2025; 81(4):1256-1268. PMCID: PMC11829732
  8. Nagesh PT, Cho Y, Zhuang Y, Babuta M, Ortega-Ribera M, Joshi R, Brezani V, Patel A, Datta AA, Brezani V, Hsieh YC, Ramos A, Mehta J, Copeland C, Kanata E, Jiang ZG, Vlachos I, Asara J; AlcHepNet Consortium (including Schnabl B); Szabo G. In vivo Bruton's tyrosine kinase inhibition attenuates alcohol-associated liver disease by regulating CD84-mediated granulopoiesis. Sci Transl Med. 2024; 16(759):eadg1915. PMCID: PMC11831603

Reviews, Editorials and Conference Summaries

  1. Schnabl B, Scholten D, Brenner DA. What is the potential role of antifibrotic agents for the treatment of liver disease? Nat Clin Pract Gastroenterol Hepatol. 2008; 5(9):496-7. PMID: 18628735
  2. Schnabl B. Peroxisome proliferator-activated receptor-d as emerging target in liver disease. Drug Dev Res. 2010; 71:106–111
  3. Brenner DA, Seki E, Taura K, Kisseleva T, Deminicis S, Iwaisako K, Inokuchi S, Schnabl B, Oesterreicher CH, Paik YH, Miura K, Kodama Y. Non-alcoholic steatohepatitis-induced fibrosis: Toll-like receptors, reactive oxygen species and Jun N-terminal kinase.Hepatol Res. 2011; 41(7):683-6. PMCID: PMC3341613
  4. Seki E, Schnabl B. Role of innate immunity and the microbiota in liver fibrosis: Crosstalk between the liver and gut. J Physiol. 2012; 590(Pt 3):447-58. PMCID: PMC3379693
  5. Yan AW, Schnabl B. Bacterial translocation and changes in the intestinal microbiome associated with alcoholic liver disease. World J Hepatol. 2012; 4(4):110-8. PMCID: PMC3345535
  6. Hartmann P, Chen W, Schnabl B. The intestinal microbiome and the leaky gut as therapeutic targets in alcoholic liver disease. Front Physiol. 2012; 3:402. PMCID: PMC3468817
  7. Brenner DA, Kisseleva T, Scholten D, Paik YH, Iwaisako K, Inokuchi S, Schnabl B, Seki E, De Minicis S, Oesterreicher C, Taura K. Origin of myofibroblasts in liver fibrosis. Fibrogenesis Tissue Repair. 2012; 5(Suppl 1):S17. PMCID: PMC3368775
  8. Schnabl B, Brenner DA. Fibroblast growth factor inducible 14 as potential target in patients with alcoholic hepatitis. Gut. 2013; 62(3):335-6. PMCID: PMC4077188
  9. Schnabl B. Linking intestinal homeostasis and liver disease. Curr Opin Gastroenterol. 2013; 29(3):264-70. PMCID: PMC4077188
  10. Schnabl B. Transplanting a fibrogenic microbiota. Hepatology. 2014; 59(5):1660-1. PMID: 24676698
  11. Schnabl B, Brenner DA. Interactions between the intestinal microbiome and liver diseases. Gastroenterology. 2014; 146(6):1513-24. PMCID: PMC3996054
  12. Jalan R, Fernandez J, Weist R, Schnabl B, Moreau R, Angeli P, Stadlbauer V, Gustot T, Bernardi M, Canton R, Albillos A, Lammert F, Wilmer A, Mookerjee R, Vila J, Garcia-Martinez R, Wendon J, Such J, Cordoba J, Sanyal A, Garcia-Tsao G, Arroyo V, Ginès P. Bacterial Infections in Cirrhosis. A position statement based on the EASL Special Conference. J Hepatol. 2014; 60(6):1310-24. PMID: 24530646
  13. Chen P, Schnabl B. Host-microbiome interactions in alcoholic liver disease. Gut Liver. 2014; 8(3):237-241. PMCID: PMC4026639
  14. Schnabl B. The Microbiome and the Liver. Gastroenterol Hepatol (N Y). 2014; 10(8):519-21. PMCID: PMC5566188
  15. Hartmann P, Seebauer CT, Schnabl B. Alcoholic liver disease: The gut microbiome and liver crosstalk. Alcohol Clin Exp Res. 2015; 39(5):763-75. PMCID: PMC4402724
  16. Llorente C, Schnabl B. The gut microbiota and liver disease. Cell Mol Gastroenterol Hepatol. 2015; 1(3):275–284. PMCID: PMC4467911
  17. Brandl K, Schnabl B. Is intestinal inflammation linking dysbiosis to gut barrier dysfunction during liver disease? Expert Rev Gastroenterol Hepatol. 2015; 9(8):1069-76. PMCID: PMC4828034
  18. Bernardi M, Moreau R, Angeli P, Schnabl B, Arroyo V. Mechanisms of decompensation and organ failure in cirrhosis: from peripheral arterial vasodilation to systemic inflammation hypothesis. J Hepatol. 2015; 63(5):1272-84. PMID: 26192220
  19. Brenner DA, Paik YH, Schnabl B. Role of Gut Microbiota in Liver Disease. J Clin Gastroenterol. 2015; 49 Suppl 1:S25-7. PMCID: PMC4602394
  20. Ho SB, Matheny ME, Schnabl B. Changes in hospital admissions and mortality for complications of cirrhosis: implications for clinicians and health systems. Gut Liver. 2016; 10(1):8-9. PMCID: PMC4694728
  21. Nakamoto N, Schnabl B. Does the intestinal microbiota explain differences in the epidemiology of liver disease between East and West? Inflamm Intest Dis. 2016; 1(1):3-8. PMCID: PMC4883108
  22. Schnabl B. Liver Capsule: Mechanisms of Alcoholic Hepatitis. Hepatology. 2016; 64(1):276. PMID: 26867027
  23. Fuchs M, Schnabl B. Editors' Introduction to the NAFLD and NASH Special Issue. Dig Dis Sci. 2016; 61(5):1211-3. PMID: 27068170
  24. Arroyo V, Moreau R, Kamath PS, Jalan R, Gines P, Nevens F, Fernandez J, To U, Garcia-Tsao G, Schnabl B. Acute-on-chronic liver failure in cirrhosis. Nature Reviews Disease Primers. 2016; 2:16041. PMID: 27277335
  25. Chen P, Miyamoto Y, Mazagova M, Lee KC, Eckmann L, Schnabl B. Microbiota and alcoholic liver disease. Alcohol Clin Exp Res. 2016; 40(8):1791-2. PMID: 27364225
  26. Llorente C, Schnabl B. Fast-Track Clearance of Bacteria from the Liver. Cell Host Microbe. 2016; 20(1):1-2. PMID: 27414492
  27. Stärkel P, Schnabl B. Bidirectional communication between liver and gut during alcoholic liver disease. Semin Liver Dis. 2016; 36(4):331-339. PMID: 27997973
  28. Bluemel S, Williams B, Knight R, Schnabl B. Precision medicine in alcoholic and non-alcoholic fatty liver disease via modulating the gut microbiota. Am J Physiol Gastrointest Liver Physiol. 2016; 311(6):G1018-G1036. PMCID: PMC5206291
  29. Brandl K, Schnabl B. Intestinal microbiota and Nonalcoholic Steatohepatitis. Curr Opin Gastroenterol. 2017; 33(3):128-133. PMCID: PMC5662009
  30. Hendrikx T, Schnabl B. Lamin Deficiency in the Liver Sets the Stage for Nonalcoholic Steatohepatitis development in males. Cell Mol Gastroenterol and Hepatol. 2017; 4(3):441-442. PMCID: PMC5650600
  31. Boule LA, Ju C, Agudelo M, Parira T, Cannon A, Davis B, Eby J, Cresci G, Samuelson DR, Shukla P, Alrefai WA, Sureshchandra S, Pandey SC, Schnabl B, Curtis BJ, Wyatt TA, Choudhry MA, Kovacs Summary of the 2016 Alcohol and Immunology Research Interest Group (AIRIG) meeting. Alcohol. 2018; 66:35-43. PMCID: PMC5743588
  32. Hochrath K, Schnabl B. Check your microbiota when taking the drug. Hepatology. 2018; 67(1):18-20. PMID: 28782199
  33. Stärkel P, Leclercq S, de Timary P, Schnabl B. Intestinal dysbiosis and permeability: the yin and yang in alcohol dependence and alcoholic liver disease. Clin Sci (Lond). 2018; 132(2):199-212. PMID: 29352076
  34. Inamine T, Schnabl B. Immunoglobulin A and Liver Diseases. Journal of Gastroenterology. 2018; 53(6):691-700. PMCID: PMC5971039
  35. Chu H, Williams B, Schnabl B. Gut microbiota, fatty liver disease, and hepatocellular carcinoma. Liver Research. 2018; 2(1):43-51. PMCID: PMC6223644
  36. Hartmann P, Schnabl B. Risk factors for progression of and treatment options for NAFLD in children. Clinical Liver Disease. 2018; 11(1):11-15. PMCID: PMC5881937
  37. Tripathi A, Debelius J, Brenner DA, Karin M, Loomba R, Schnabl B, Knight R. The gut-liver axis and the intersection with the microbiome. Nat Rev Gastroenterol Hepatol. 2018; 15(12):785. PMCID: PMC7133393
  38. Marrero I, Maricic I, Feldstein AE, Loomba R, Schnabl B, Rivera-Nieves J, Eckmann L, Kumar V. Complex Network of NKT Cell Subsets Controls Immune Homeostasis in Liver and Gut. Frontiers Immunology. 2018; 9:2082. PMCID: PMC6141878
  39. Brandl K, Hartmann P, Jih LJ, Pizzo DP, Schnabl B. Reply to: “Finding fibroblast growth factor 19 during cholestasis: Does x mark the spot?” J Hepatol. 2018; 69(6):1400-1401. PMID: 30301625
  40. Chu H, Duan Y, Yang L, Schnabl B. Small Metabolites, Possible Big Changes: a Microbiota-centered View of Non-alcoholic Fatty Liver Disease. Gut. 2019; 68(2):359-370. PMID: 30171065
  41. Allaband C, McDonald D, Vázquez-Baeza Y, Minich JJ, Tripathi A, Brenner DA, Loomba R, Smarr L, Sandborn WJ, Schnabl B, Dorrestein P, Zarrinpar A, Knight R. Microbiome 101: Studying, Analyzing, and Interpreting Gut Microbiome Data for Clinicians. Clin Gastroenterol Hepatol. 2019; 17(2):218-230. PMCID: PMC6391518
  42. Hendrikx T, Schnabl B. Antimicrobial proteins: intestinal guards to protect against liver disease. Journal of Gastroenterology. 2019; 54(3):209-217. PMCID: PMC639196
  43. Sarin SK, Pande A, Schnabl B. Microbiome as a therapeutic target in alcoholic liver disease. J Hepatol. 2019; 70(2):260-272. PMID: 30658727
  44. Szabo G, Kamath PS, Shah VH, Thursz M, Mathurin P. EASL-AASLD Joint Meeting Collaborators: Addolorato G, Bataller R, Burra P, Castera L, Cortez Pinto H, Diehl AM, Gao B, Gilmore SI, Hampe J, Jürgen R, Karin M, Krag A, Leon D, Leptak C, Louvet A, Lucey M, McClain C, Nagy L, Pageaux GP, Sanyal A, Schnabl B, Tiniakos D, Trautwein C, Tsukamoto H. Alcohol-Related Liver Disease: Areas of Consensus, Unmet Needs and Opportunities for Further Study. Hepatology. 2019; 69(5):2271-2283. PMID: 30645002
  45. Hendrikx T, Schnabl B. Indoles: metabolites produced by intestinal bacteria capable of controlling liver disease manifestation. Journal of Internal Medicine. 2019; 286(1):32-40. PMID: 30873652
  46. Hartmann P, Chu H, Duan Y, Schnabl B. Gut microbiota in liver disease: Too much is harmful, nothing at all is not helpful either. Am J Physiol Gastrointest Liver Physiol. 2019; 316(5):G563-G573. PMCID: PMC6580239
  47. Zhou R, Fan X, Schnabl B. Role of the Intestinal Microbiome in Liver Fibrosis Development and New Treatment Strategies. Translational Research. 2019; 209:22-38. PMID: 30853445
  48. Avila MA, Dufour JF, Gerbes AL, Zoulim F, Bataller R , Burra P, Cortez-Pinto H, Gao B, Gilmore I, Mathurin P, Moreno C, Poznyak V, Schnabl B, Szabo G, Thiele M, Thursz M. Recent advances in alcohol-related liver disease (ALD): summary of a Gut round table meeting. Gut. 2019; 69(4):764-780. PMCID: PMC7236084
  49. Neuman MG, Seitz HK, French SW, Malnick S, Tsukamoto H, Cohen LB, Hoffman P, Tabakoff B, Fasullo M, Nagy LE, Tuma PL, Schnabl B, Mueller S, Groebner JL, Barbara FA, Yue J, Nikko A, Alejandro M, Brittany T, Edward V, Harrall K, Saba L, Mihai O. Alcoholic-Hepatitis, Links to Brain and Microbiome: Mechanisms, Clinical and Experimental Research. Biomedicines. 2020; 8(3). pii: E63. PMCID: PMC7148515
  50. Jiang L, Schnabl B. Gut microbiota in liver disease: what do we know and what do we not know? Physiology (Bethesda). 2020; 35(4):261-274. PMCID: PMC7474259
  51. Lang S, Schnabl B. Microbiota and Fatty Liver Disease—the Known, the Unknown, and the Future. Cell Host Microbe. 2020; 28(2):233-244. PMCID: PMC746784
  52. Mendes BG, Schnabl B. From intestinal dysbiosis to alcohol-associated liver disease. Clin Mol Hepatol. 2020; 26(4):595-605. PMCID: PMC7641547
  53. Lang S, Demir M, Schnabl B. Targeting pathobionts for the treatment of alcohol-associated liver disease. Liver Int. 2021; 41(1):239-240. PMCID: PMC7772232
  54. Gao B, Emami A, Nath S, Schnabl B. Microbial Products and Metabolites Contributing to Alcohol-Related Liver Disease. Mol Nutr Food Res. 2021; 65(5):e2000023. PMCID: PMC7758187
  55. Sharpton SR, Schnabl B, Knight R, Loomba R. Current Concepts, Opportunities, and Challenges of Gut Microbiome-Based Personalized Medicine in Nonalcoholic Fatty Liver Disease. Cell Metab. 2021; 33(1):21-32. PMCID: PMC8414992
  56. Jiang L, Stärkel P, Fan JG, Fouts DE, Bacher P, Schnabl B. The gut mycobiome: a novel player in chronic liver diseases. J Gastroenterol. 2021; 56(1):1-11. PMCID: PMC7819863
  57. Wang R, Tang R, Li B, Ma X, Schnabl B, Tilg H. Gut microbiome, liver immunology, and liver diseases. Cell Mol Immunol. 2021; 18(1):4-17. PMCID: PMC7852541
  58. Hasan A, Hasan LK, Schnabl B, Greytak M, Yadlapati R. Microbiome of the Aerodigestive Tract in Health and Esophageal Disease. Dig Dis Sci. 2021; 66(1):12-18. PMCID: PMC8006547
  59. Hartmann P, Schnabl B. New Developments in Microbiome in Alcohol-Associated and Nonalcoholic Fatty Liver Disease. Semin Liver Dis. 2021; 41(1):87-102. PMCID: PMC8163568
  60. Trebicka J, Macnaughtan J, Schnabl B, Shawcross DL, Bajaj JS. The microbiota in cirrhosis and its role in hepatic decompensation. J Hepatol. 2021; 75 Suppl 1:S67-S81. PMCID: PMC8973011
  61. Fairfield B, Schnabl B. Gut dysbiosis as a driver in alcohol-induced liver injury. JHEP Rep. 2020; 3(2):100220. PMCID: PMC7868813
  62. Gao B, Chi L, Zhu Y, Shi X, Tu P, Li B, Yin J, Gao N, Shen W, Schnabl B. An Introduction to Next Generation Sequencing Bioinformatic Analysis in Gut Microbiome Studies. Biomolecules. 2021; 11(4):530. PMCID: PMC8066849
  63. Tranah TH, Edwards LA, Schnabl B, Shawcross DL. Targeting the gut-liver-immune axis to treat cirrhosis. Gut. 2021; 70(5):982-994. PMID: 33060124
  64. Hsu CL, Duan Y, Fouts DE, Schnabl B. Intestinal virome and therapeutic potential of bacteriophages in liver disease. J Hepatol. 2021; 75(6):1465-1475. PMCID: PMC8929164
  65. Duan Y, Young R, Schnabl B. Bacteriophages and their potential for treatment of gastrointestinal diseases. Nat Rev Gastroenterol Hepatol. 2022; 19(2):135-144. PMCID: PMC8966578
  66. Schnabl B. Update on the Role of the Gut Microbiota on Alcohol-Associated Liver Disease. Gastroenterol Hepatol (N Y). 2021; 17(8):381-383. PMCID: PMC8475262
  67. Jiang L, Wang Y, Xiao Y, Wang Y, Yan J, Schnabl B, Cai W. Role of the Gut Microbiota in Parenteral Nutrition-Associated Liver Disease: From Current Knowledge to Future Opportunities. J Nutr. 2022; 152(2):377-385. PMID: 34734271
  68. Maccioni L, Leclercq IA, Schnabl B, Stärkel P. Host Factors in Dysregulation of the Gut Barrier Function during Alcohol-Associated Liver Disease. Int J Mol Sci. 2021; 22(23):12687. PMCID: PMC8657823
  69. Bajaj JS#, Ng SC#, Schnabl B#. Promises of microbiome-based therapies. J Hepatol. 2022; 76(6):1379-1391. PMCID: PMC9588437
  70. Schnabl B, Arteel GE, Stickel F, Hengstler J, Vartak N, Ghallab A, Dooley S, Li Y, Schwabe RF. Liver specific, systemic and genetic contributors to alcohol-related liver disease progression. Z Gastroenterol. 2022; 60(1):36-44. PMCID: PMC8941985
  71. Philips CA, Schnabl B, Bajaj JS. Gut Microbiome and Alcohol-associated Liver Disease. J Clin Exp Hepatol. 2022; 12(5):1349-1359. PMCID: PMC9499847
  72. Zeng S, Schnabl B. Roles for the mycobiome in liver disease. Liver Int. 2022; 42(4):729-741. PMCID: PMC8930708
  73. Hasa E, Hartmann P, Schnabl B. Liver cirrhosis and immune dysfunction. Int Immunol. 2022; 34(9):455-466. PMCID: PMC9447994
  74. Philips CA, Schnabl B, Bajaj JS. Gut Microbiome and Alcohol-associated Liver Disease. J Clin Exp Hepatol. 2022; 12(5):1349-1359. PMCID: PMC9499847
  75. Hartmann P, Schnabl B. Can a mucosal microbiota signature predict disease severity, survival, and disease recurrence in PSC? Hepatology. 2023; 77(3):709-711. PMID: 36626635
  76. Hartmann P, Schnabl B. Fungal infections and the fungal microbiome in hepatobiliary disorders. J Hepatol. 2023; 78(4):836-851. PMCID: PMC10033447
  77. Hsu CL, Schnabl B. The gut-liver axis and gut microbiota in health and liver disease. Nat Rev Microbiol. 2023; 21(11):719-733. PMCID: PMC10794111
  78. Fondevila MF, Schnabl B. Intestinal clock modulates rhythmic hepatic metabolism. J Hepatol. 2023; 79(3):589-591. PMID: 37290589
  79. Cheng Z, Chen Y, Schnabl B, Chu H, Yang L. Bile acid and nonalcoholic steatohepatitis: Molecular insights and therapeutic targets. J Adv Res. 2024; 59:173-187. PMCID: PMC11081971
  80. Ranjbarian T, Schnabl B. Gut Microbiome-Centered Therapies for Alcohol-Associated Liver Disease. Semin Liver Dis. 2023; 43(3):311-322. PMID: 37527781
  81. Fujiki J, Schnabl B. Phage therapy: Targeting intestinal bacterial microbiota for the treatment of liver diseases. JHEP Rep. 2023; 5(12):100909. PMCID: PMC10641246
  82. Özdirik B, Schnabl B. Microbial Players in Primary Sclerosing Cholangitis: Current Evidence and Concepts. Cell Mol Gastroenterol Hepatol. 2024; 17(3):423-438. PMCID: PMC10837305
  83. Schnabl B. PPAR Agonists in Primary Biliary Cholangitis. N Engl J Med. 2024; 390(9):855-858. PMID: 38381666
  84. Meijnikman AS, Nieuwdorp M, Schnabl B. Endogenous ethanol production in health and disease. Nat Rev Gastroenterol Hepatol. 2024; 21(8):556-571. PMID: 38831008
  85. Schöler D, Schnabl B. The role of the microbiome in liver disease. Curr Opin Gastroenterol. 2024; 40(3):134-142. PMCID: PMC10990783
  86. Yang Y, Schnabl B. Gut Bacteria in Alcohol-Associated Liver Disease. Clin Liver Dis. 2024; 28(4):663-679. PMCID: PMC11450261
  87. Zeng S, Schnabl B. Gut mycobiome alterations and implications for liver diseases. PLoS Pathog. 2024; 20(8):e1012377. PMCID: PMC11309506
  88. Burra P, Zanetto A, Schnabl B, Reiberger T, Montano-Loza AJ, Asselta R, Karlsen TH, Tacke F. Hepatic immune regulation and sex disparities. Nat Rev Gastroenterol Hepatol. 2024; 21(12):869-884. PMID: 39237606.
  89. Yamazaki T, Cable EE, Schnabl B. Peroxisome proliferator-activated receptor delta and liver diseases. Hepatol Commun. 2025; 9(2):e0646. PMID: 39899669
  90. Yamazaki T, Schnabl B. Acute alcohol-associated hepatitis: Latest findings in non-invasive biomarkers and treatment. Liver Int. 2025; 45(3):e15608. PMCID: PMC10646153
  91. Saha S, Schnabl B. Modulating the microbiome in chronic liver diseases - current evidence on the role of fecal microbiota transplantation. Expert Rev Gastroenterol Hepatol. 2025; 19(1):53-64. PMID: 39760535.
  92. Hu Y, Schnabl B, Stärkel P. Origin, Function, and Implications of Intestinal and Hepatic Macrophages in the Pathogenesis of Alcohol-Associated Liver Disease. Cells. 2025; 14(3):207. PMCID: PMC11816606
  93. Schnabl B, Damman CJ, Carr RM. Metabolic dysfunction-associated steatotic liver disease and the gut microbiome: pathogenic insights and therapeutic innovations. J Clin Invest. 2025; 135(7):e186423. PMCID: PMC11957707
  94. Kreimeyer H, Llorente C, Schnabl B. Influence of Alcohol on the Intestinal Immune System. Alcohol Res. 2025; 45(1):03. PMCID: PMC11913448
  95. Støy S, Schnabl B. Role of Intestinal Microbiome in Potentiating Inflammation and Predicting Outcomes in Alcohol-Associated Cirrhosis. Gastroenterol Clin North Am. 2025; 54(2):453-467. PMCID: PMC12066832
  96. Meijnikman AS, Fondevila MF, Arrese M, Kisseleva T, Bataller R, Schnabl B. Towards more consistent models and consensual terminology in preclinical research for Steatotic Liver Disease. J Hepatol. 2024. PMID: 39581500
  97. Shi Y, Chen Z, Fang T, Chen X, Deng Y, Qin H, Lian M, Shen J, Zong Y, Chu H, Hoebinger C, Guo H, Yuan Z, Zheng J, Zhou Y, Pan Y, Mendes BG, Lang S, Hendrikx T, Zeng S, Cao H, Yang L, Chen L, Chen P, Dai L, Wang H, Yin S, Zhu S, Ma X, Schnabl B, Chen H, Duan Y. Gut microbiota in treating inflammatory digestive diseases: Current challenges and therapeutic opportunities. Imeta. 2024 Dec 31;4(1):e265. PMCID: PMC11865350.
  98. Harberts A, Schnabl B. Microbiota in Alcohol-associated Organ Damage. Am J Pathology. 2025, accepted
  99. Wei W, Schnabl B Unlocking the potential of the gut microbiome in liver regeneration: Benefits and mechanistic insights. Acta Pharm Sin B 2025; 15(3):1715-1716. PMCID: PMC12069235

Book Chapters

  1. Schnabl B. Metagenomic applications and the potential for understanding chronic liver disease. In Nelson KE, Editor. Metagenomics of the Human Body. Springer; 2010: 277-296.
  2. Brandl K, Schnabl B. Liver Disease: Interactions with the Intestinal Microbiota. In Luigi Nibali and Brian Henderson, Editors. The human microbiota and chronic disease – dysbiosis as a cause of human pathology. Wiley Blackwell; 2016: 339-349.
  3. Hartmann P, Schnabl B. Translocation of bacteria and bacterial products from the intestinal lumen in cirrhosis. Role of microbiota, intestinal mucosal integrity and local immune function. In Vincente Arroyo and Mauro Bernardi, Editors. Systemic inflammation and organ failure in cirrhosis. The Acute-on-Chronic Liver Failure syndrome (ACLF). Elsevier; 2016: 35-41.
  4. Baeckhed F, Schnabl B, Li J. Metabolism and microbiota. In Kristin Wannerberger, Editor. Microbiome: The human microbiota in health and disease. Ferring International Center SA; 2019: 33-55.
  5. Schnabl B. Alcohol-associated liver disease. In Joseph Loscalzo, Anthony S. Fauci, Dennis L. Kasper, Stephen L. Hauser, Dan L. Longo, J. Larry Jameson, Editors. 21st Edition of Harrison 's Principles of Internal Medicine. McGraw Hill; 2022: 2617-2619
  6. Schnabl B. Alcohol-associated liver disease. In Joseph Loscalzo, Anthony S. Fauci, Dennis L. Kasper, Stephen L. Hauser, Dan L. Longo, J. Larry Jameson, Editors. 22st Edition of Harrison 's Principles of Internal Medicine. McGraw Hill; 2025
  7. Best J, Schnabl B, Canbay A. MASLD and Hepatic/Extrahepatic Cancers: Understanding the Complex Relationship. In Nahum Méndez-Sánchez, Xingshun Qi, Editors. Metabolic Dysfunction-Associated Steatotic Liver Disease. Springer; 2024, 95-106